Metformin Viatris

Metformin, the active ingredient in Metformin Viatris, is a biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Metformin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Viatris is indicated for management of disorders related to glucose metabolism, primarily type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels.

Metformin Viatris may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate, presenting with rapid breathing and muscle pain. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: marked liver enzyme elevation or liver dysfunction. - Hypoglycaemia: rare when combined with other glucose‑lowering agents. - Acute pancreatitis: sudden abdominal pain with elevated enzymes.

Before initiating Metformin Viatris, consider the following safety measures. - Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Hepatic function monitoring: use caution in those with liver disease. - Lactic acidosis risk: discontinue before radiographic contrast procedures. - Concomitant medication review: evaluate for drugs that may increase metformin levels. - Elderly dose adjustment: start with lower dose and titrate slowly. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Viatris can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; discontinue metformin before and after use. - Alcohol excess: increases risk of lactic acidosis. - Strong CYP450 inhibitors (e.g., trimethoprim): raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - Corticosteroids: may raise blood glucose, requiring dose adjustment. - ACE inhibitors: monitor renal function and electrolytes. - NSAIDs: may impair renal function, increasing metformin exposure.